In another epidemiological study using the Danish nationwide health registries, the three year risk of gout was assessed in 11,047 pairs of matched SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP1-RA) users (61). Here, SLC5A2 is linked to gout.